(Total Views: 505)
Posted On: 05/25/2025 8:14:52 AM
Post# of 155669
TMZ / Glio is identical situation to our mTNBC
-Trovdely & TMZ only treat a very small %.
With both being cold tumors;
Again, from our patent app:
Resistance of GBM is a serious problem, preventing effective treatment. The EANO and International Brain Tumor Study Group demonstrated that dose intensification fails to improve patient survival [17,42].
The combination of TMZ (standard maintenance chemotherapeutic in GBM) and Irradiation (Canton trial) prolonged survival only in patients with IDH-mutant astrocytoma WHO grade 3 and not in those with GBM [43].
The prolongation of TMZ treatment from 6 to 12 cycles extended neither progression-free nor overall survival [44].
___
Google:
IDH-mutant astrocytoma WHO grade 3 tumors occur in a percentage of glioblastoma patients, but it's important to clarify that IDH-mutant astrocytomas are primarily found in lower-grade gliomas (grades II and III), not glioblastoma (WHO grade IV). Specifically, IDH-mutant astrocytomas are commonly observed in anaplastic astrocytomas (grade III), with reports ranging from 54%. While some studies may mention IDH mutations in glioblastoma (grade IV), the frequency is significantly lower, generally reported as 15-20%.
___
So double check & confirms TMZ is "not glioblastoma". But it is a combo SOC for low grade.
Cytodyn March letter:
" CytoDyn is also in discussions with several KOLs in neuro-oncology about the possibility of initiating a pilot study in patients with GBM, also based on currently available data."
GBM is another oyster Leronlimab is about to crack wide-open....
mTNBC
CRC
GBM
-Trovdely & TMZ only treat a very small %.
With both being cold tumors;
Again, from our patent app:
Resistance of GBM is a serious problem, preventing effective treatment. The EANO and International Brain Tumor Study Group demonstrated that dose intensification fails to improve patient survival [17,42].
The combination of TMZ (standard maintenance chemotherapeutic in GBM) and Irradiation (Canton trial) prolonged survival only in patients with IDH-mutant astrocytoma WHO grade 3 and not in those with GBM [43].
The prolongation of TMZ treatment from 6 to 12 cycles extended neither progression-free nor overall survival [44].
___
Google:
IDH-mutant astrocytoma WHO grade 3 tumors occur in a percentage of glioblastoma patients, but it's important to clarify that IDH-mutant astrocytomas are primarily found in lower-grade gliomas (grades II and III), not glioblastoma (WHO grade IV). Specifically, IDH-mutant astrocytomas are commonly observed in anaplastic astrocytomas (grade III), with reports ranging from 54%. While some studies may mention IDH mutations in glioblastoma (grade IV), the frequency is significantly lower, generally reported as 15-20%.
___
So double check & confirms TMZ is "not glioblastoma". But it is a combo SOC for low grade.
Cytodyn March letter:
" CytoDyn is also in discussions with several KOLs in neuro-oncology about the possibility of initiating a pilot study in patients with GBM, also based on currently available data."
GBM is another oyster Leronlimab is about to crack wide-open....
mTNBC
CRC
GBM
(3)
(0)
